Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene in AUD with Comorbid BPD
NCT02752503Unknown
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nalmefene in alcohol use disorder (AUD) and borderline personality disorder (BPD), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Days of excessive alcohol intake at 2 months and Daily average intake at 2 months. Status: unknown.
02
Drugs
nalmefene
03
Conditions
alcohol use disorder (AUD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT02752503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752503.